Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Wugen, Inc.

News headline image
Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Present Data on WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Announces CEO Transition
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Present at the Upcoming Jefferies London Healthcare Conference
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Present Data Characterizing WU-NK-101 at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Present Data on WU-NK-101 for Relapsed / Refractory Acute Myelogenous Leukemia at The American Society of Hematology’s (ASH) 64th Annual Meeting
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Present at the Upcoming Jefferies Cell & Genetic Medicine Summit
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Appoints Natalie Mount, Ph.D., as Chair of the Board of Directors
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Receives U.S. FDA Fast Track and Rare Pediatric Disease Designations for WU-CART-007 for the Treatment of R/R T-ALL/LBL
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Presents New Preclinical Data Demonstrating Enhanced Anti-Tumor Activity of WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Participate in Upcoming June Investor Conferences
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Present Preclinical Data on WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Participate in Upcoming April Investor Conferences
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Present at the Innate Killer Summit 2022
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Presents New Preclinical Data Supporting the Safety and Efficacy of WU-CART-007 for T-Cell Malignancies at the 63rd Annual Society of Hematology (ASH) Annual Meeting
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
From Wugen, Inc.
Via Business Wire
News headline image
Wugen to Present Virtually at the Upcoming Jefferies London Healthcare Conference
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Announces Data Presentation at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Announces Data Presentation at the 63rd Annual Society of Hematology (ASH) Annual Meeting
From Wugen, Inc.
Via Business Wire
News headline image
Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials
From Wugen, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.